VTechWorks staff will be away for the Thanksgiving holiday starting November 24 through November 28, and will not be replying to requests during this time. Thank you for your patience.

Show simple item record

dc.contributor.authorQi, Junen
dc.date.accessioned2014-03-14T21:10:12Zen
dc.date.available2014-03-14T21:10:12Zen
dc.date.issued2010-02-18en
dc.identifier.otheretd-04012010-223908en
dc.identifier.urihttp://hdl.handle.net/10919/37537en
dc.description.abstractProstate cancer is the most common non-skin cancer for men in America. The androgen receptor exerts transcriptional activity and plays an important role for the proliferation of prostate cancer cells. Androgen receptor ligands bind the androgen receptor and inhibit its transcriptional activity effectively. However, prostate cancer can progress to hormone refractory prostate cancer (HRPC) to avoid this effect. Chemotherapies are currently the primary treatments for HRPC. Unfortunately, none of the available chemotherapies are curative. Among them, paclitaxel and docetaxel are two of the most effective drugs for HRPC. More importantly, docetaxel is the only form of chemotherapy known to prolong survival in the HRPC patients. We hypothesized that the conjugation of paclitaxel or docetaxel with an androgen receptor ligand will overcome the resistance mechanism of HRPC. Eleven conjugates were designed, synthesized and biologically evaluated. Some of them were active against androgen-independent prostate cancer, but they were all less active than paclitaxel and docetaxel. Discodermolide is a microtubule interactive agent, and has a similar mechanism of action to paclitaxel. Interestingly, discodermolide is active against paclitaxel-resistant cancer cells and can synergize with paclitaxel, which make it an attractive anticancer drug candidate. Understanding the bioactive conformation of discodermolide is important for drug development, but this task is difficult due to the linear and flexible structure of discodermolide. Indirect evidence for the orientation of discodermolide in the tubulin binding pocket can be obtained from fluorescence spectroscopy of the discodermolide tubulin complex. For this purpose, we designed and synthesized a simplified fluorescently labeled discodermolide analog, and it was active in the tubulin assembly bioassay. In addition, a conformationally constrained discodermolide was designed to mimic the bioactive conformation according to computational modeling. The synthetic effort was made, but failed during one of the final steps.en
dc.publisherVirginia Techen
dc.relation.haspartQi_J_D_2010.pdfen
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectdocetaxelen
dc.subjectpaclitaxelen
dc.subjecttaxolen
dc.subjecttubulin binding conformationen
dc.subjectfluorescenceen
dc.subjectdiscodermolideen
dc.subjectmicrotubulesen
dc.subjecttubulinen
dc.subjectandrogen receptoren
dc.subjectcyanonilutamideen
dc.titleDesign, Syntheses and Bioactivities of Androgen Receptor Targeted Taxane Analogs, Simplified Fluorescently Labeled Discodermolide Analogs, and Conformationally Constrained Discodermolide Analogsen
dc.typeDissertationen
dc.contributor.departmentChemistryen
dc.description.degreePh. D.en
thesis.degree.namePh. D.en
thesis.degree.leveldoctoralen
thesis.degree.grantorVirginia Polytechnic Institute and State Universityen
thesis.degree.disciplineChemistryen
dc.contributor.committeechairKingston, David G. I.en
dc.contributor.committeememberEtzkorn, Felicia A.en
dc.contributor.committeememberGibson, Harry W.en
dc.contributor.committeememberCarlier, Paul R.en
dc.contributor.committeememberTurner, S. Richarden
dc.identifier.sourceurlhttp://scholar.lib.vt.edu/theses/available/etd-04012010-223908/en
dc.date.sdate2010-04-01en
dc.date.rdate2010-04-22en
dc.date.adate2010-04-22en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record